Correlation Between Leap Therapeutics and Immix Biopharma

Can any of the company-specific risk be diversified away by investing in both Leap Therapeutics and Immix Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Leap Therapeutics and Immix Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Leap Therapeutics and Immix Biopharma, you can compare the effects of market volatilities on Leap Therapeutics and Immix Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Leap Therapeutics with a short position of Immix Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Leap Therapeutics and Immix Biopharma.

Diversification Opportunities for Leap Therapeutics and Immix Biopharma

0.16

Correlation Coefficient

Leap Therapeutics  Immix Biopharma

Average diversification

The 3 months correlation between Leap and Immix is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Leap Therapeutics and Immix Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immix Biopharma and Leap Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Leap Therapeutics are associated (or correlated) with Immix Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immix Biopharma has no effect on the direction of Leap Therapeutics i.e., Leap Therapeutics and Immix Biopharma go up and down completely randomly.

Pair Corralation between Leap Therapeutics and Immix Biopharma

Given the investment horizon of 90 days Leap Therapeutics is expected to generate 0.88 times more return on investment than Immix Biopharma. However, Leap Therapeutics is 1.14 times less risky than Immix Biopharma. It trades about 0.03 of its potential returns per unit of risk. Immix Biopharma is currently generating about 0.02 per unit of risk. If you would invest  286.00  in Leap Therapeutics on August 31, 2024 and sell it today you would earn a total of  9.00  from holding Leap Therapeutics or generate 3.15% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.44%
Values	Daily Returns

Leap Therapeutics  vs.  Immix Biopharma

Leap Therapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Leap Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Leap Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Immix Biopharma

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Immix Biopharma are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Immix Biopharma may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Pair Trading with Leap Therapeutics and Immix Biopharma

The main advantage of trading using opposite Leap Therapeutics and Immix Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Leap Therapeutics position performs unexpectedly, Immix Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will offset losses from the drop in Immix Biopharma's long position.

The idea behind Leap Therapeutics and Immix Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.